Are tumor cells protected from some anti-cancer drugs by elevated APC/C activity? (Comment on DOI: 10.1002/bies.201100094)

BioEssays ◽  
2011 ◽  
Vol 33 (12) ◽  
pp. 898-898
Author(s):  
Duncan J. Clarke
Keyword(s):  
Tumor Cells ◽  
Cancer Drugs ◽  
Anti Cancer

Nuclear delivery of dual anti-cancer drugs by molecular self-assembly

2021 ◽  
Vol 9 (1) ◽  
pp. 116-123
Author(s):  
Jindao Wu ◽  
Wenzhou Ding ◽  
Guoyong Han ◽  
Wei You ◽  
Wen Gao ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Tumor Cells ◽  
Self Assembly ◽  
Nuclear Accumulation ◽  
Cancer Drugs ◽  
Anti Cancer ◽  
Good Cell

Nanomedicines generally suffer from poor accumulation in tumor cells, low anti-tumor efficacy, and drug resistance. In order to address these problems, we introduced a novel nanomedicine based on dual anti-cancer drugs, which showed good cell nuclear accumulation properties.

scholarly journals Peptide fragments of Hsp70 modulate its chaperone activity and sensitize tumor cells to anti-cancer drugs

FEBS Letters ◽  
2017 ◽  
Vol 591 (24) ◽  
pp. 4074-4082 ◽  
Author(s):  
Dmitry V. Sverchinsky ◽  
Vladimir F. Lazarev ◽  
Pavel I. Semenyuk ◽  
Vladimir A. Mitkevich ◽  
Irina V. Guzhova ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Chaperone Activity ◽  
Cancer Drugs ◽  
Peptide Fragments ◽  
Anti Cancer

scholarly journals Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Pradip De ◽  
Jennifer H. Carlson ◽  
Brian Leyland-Jones ◽  
Casey Williams ◽  
Nandini Dey
Keyword(s):  
Tumor Cells ◽  
Cancer Drugs ◽  
Fluorescence Staining ◽  
Anti Cancer

A Case of Malignant Melanoma Treated with a Combination of Anti-Cancer Drugs and Biological Response Modifiers.

1993 ◽  
Vol 55 (1) ◽  
pp. 43-46
Author(s):  
Jun YOSHIDA ◽  
Juichiro NAKAYAMA ◽  
Nobuyuki SHIMIZU ◽  
Shonosuke NAGAE ◽  
Yoshiaki HORI
Keyword(s):  
Malignant Melanoma ◽  
Biological Response ◽  
Biological Response Modifiers ◽  
Cancer Drugs ◽  
Anti Cancer

Current Scenario in Structure and Ligand-Based Drug Design on Anti-colon Cancer Drugs

2019 ◽  
Vol 24 (32) ◽  
pp. 3829-3841 ◽  
Author(s):  
Lakshmanan Loganathan ◽  
Karthikeyan Muthusamy
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
Anticancer Agent ◽  
Computational Power ◽  
Cancer Drugs ◽  
Recent Advances ◽  
Anti Cancer ◽  
Drug Designing ◽  
Current Scenario ◽  
Molecular Modeling Studies

Worldwide, colorectal cancer takes up the third position in commonly detected cancer and fourth in cancer mortality. Recent progress in molecular modeling studies has led to significant success in drug discovery using structure and ligand-based methods. This study highlights aspects of the anticancer drug design. The structure and ligand-based drug design are discussed to investigate the molecular and quantum mechanics in anti-cancer drugs. Recent advances in anticancer agent identification driven by structural and molecular insights are presented. As a result, the recent advances in the field and the current scenario in drug designing of cancer drugs are discussed. This review provides information on how cancer drugs were formulated and identified using computational power by the drug discovery society.

Recent Advances on Therapeutic Peptides for Breast Cancer Treatment

2020 ◽  
Vol 21 ◽  
Author(s):  
Samad Beheshtirouy ◽  
Farhad Mirzaei ◽  
Shirin Eyvazi ◽  
Vahideh Tarhriz
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Breast Cancer Cells ◽  
Specific Binding ◽  
High Specificity ◽  
The Novel ◽  
Anti Cancer ◽  
Therapeutic Peptides ◽  
Low Toxicity

: Breast cancer is a heterogeneous malignancy which is the second cause of mortality among women in the world. Increasing the resistance to anti-cancer drugs in breast cancer cells persuades researchers to search the novel therapies approaches for the treatment of the malignancy. Among the novel methods, therapeutic peptides which target and disrupt tumor cells have been of great interest. Therapeutic peptides are short amino acids monomer chains with high specificity to bind and modulate a protein interaction of interest. Several advantages of peptides such as specific binding on tumor cells surface, low molecular weight and low toxicity on normal cells make the peptides as an appealing therapeutic agents against solid tumors, particularly breast cancer. Also, National Institutes of Health (NIH) describes therapeutic peptides as suitable candidate for the treatment of drug-resistant breast cancer. In this review, we attempt to review the different therapeutic peptides against breast cancer cells which can be used in treatment and diagnosis of the malignancy. Meanwhile, we presented an overview of peptide vaccines which have been developed for the treatment of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document